Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study |
| |
| Affiliation: | 1. IBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;2. Gastroenterology Unit, A.O. Ordine Mauriziano, Turin, Italy;3. IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Italy;4. Gastroenterology Unit, Department Surgery, Oncology and Gastroenterology, University of Padua, Italy;5. General and Specialistic Medicine/Gastroenterology, Città della Salute e della Scienza di Torino, Italy;6. University of Rome Tor Vergata, Department of Systems Medicine, Gastroenterology, Rome, Italy;7. Federico II University, Gastroenterology, Naples, Italy;8. Gastroenterologia ed Endoscopia Digestiva Aziendale USL Umbria1, Perugia, Italy;9. Gastroenterology and Hepatology Section, DiBiMis, University of Palermo, Palermo, Italy;10. Gastrointestinal Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy;11. Department of Pathophysiology and Transplantation, University of Milan and Gastroenterology and Endoscopy Unit, IRCCS Cà Granda, IRCCS Policlinico Hospital, Milan, Italy;12. IBD Unit, San Filippo Neri Hospital, Rome, Italy;13. Department of New Technologies and Translational Research in Medicine and Surgery, University of Pisa, Pisa, Italy;14. Luigi Sacco University Hospital, Gastroenterology and IBD Unit, Milan, Italy;15. Gastroenterology Unit, San Nicola Pellegrino Hospital, Trani, Italy;p. Division of Gastroenterology, “Brotzu” Hospital, Cagliari, Italy;q. Department of Internal Medicine, Gastroenterology Unit, University of Modena and Reggio Emilia, Modena, Italy;r. Department of Dermatology, Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, Rome, Italy;s. Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, Rome, Italy;t. Università Cattolica del Sacro Cuore, Rome, Italy |
| |
| Abstract: | BackgroundFew data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis.Aimsto describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription.MethodsThis multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD.ResultsSeventy patients (64 Crohn’s disease / 6 ulcerative colitis) were enrolled. The median follow-up on ustekinumab therapy was 10.7 months (range, 1.4–67.3). Twelve patients (17.1%) withdrew the treatment after a median of 7.4 months (range, 0.9–23.8). The cumulative probability of maintaining ustekinumab treatment was 97.1% at 6 months and 77.1% at 12 months. Among the 56 patients with baseline active IBD, 34 (60.7%) were in clinical remission at the last follow-up visit. Their cumulative probability of achieving clinical remission was 84.7% and 63.9% at 6 and 12 months, respectively. Two patients stopped ustekinumab for an adverse event.ConclusionsSubcutaneous ustekinumab had a good effectiveness profile for IBD patients treated for concomitant dermatological or rheumatological conditions. |
| |
| Keywords: | Crohn’s disease Psoriasis Psoriatic arthritis Ulcerative colitis Ustekinumab |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
